Cell signalling and cancer: Characterisation of therapeutic targets

被引:1
|
作者
de Cremoux, P. [2 ]
Robert, J. [1 ]
机构
[1] Univ Bordeaux Segalen, Inst Bergonie, Inserm U916, F-33076 Bordeaux, France
[2] Univ Paris Diderot, Hop St Louis, F-75010 Paris, France
来源
PATHOLOGIE BIOLOGIE | 2012年 / 60卷 / 04期
关键词
Cell signalling; Cancer; Cell proliferation; MAP kinase pathway; Tyrosine kinase receptors; RAS protein; RAF protein; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; LUNG-CANCER; PATHWAY; ONCOLOGY;
D O I
10.1016/j.patbio.2012.05.006
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Cellular communication is required for the life of pluricellular organisms. The informations exchanged between cells belong to six major types of order to be executed, opposite each other: proliferate or differentiate; remain attached or migrate; survive or die. The cancer cell is genetically unstable, able to explore all the functions encoded by the genome and to consider every proliferative or migratory advantage for selecting it and transmit it to its descent. All the signalling pathways involved in proliferation or differentiation, in adhesion and migration, in survival and death may be altered by oncogenic alterations. These alterations are precisely those which can be targeted for therapy: from this observation was forged the concept of targeted therapy. We present here some examples of therapeutic targeting at the level of a major proliferation pathway by showing how it was possible to identify and characterise relevant targets, invent original new therapeutic tools and decipher the mechanisms of resistance which occur and hinder the success of targeted therapies. This example is the proliferation signalling pathway which starts from the activation of tyrosine kinase receptors by cognate growth factors and ends by the activation of transcription factors which trigger the transcription of the genes required for DNA replication, after undergoing through numerous intermediate molecules constituting the MAP kinase pathway: RAS, RAF, MEK and ERK. (C) 2012 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 50 条
  • [1] WNT signalling pathways as therapeutic targets in cancer
    Jamie N. Anastas
    Randall T. Moon
    Nature Reviews Cancer, 2013, 13 : 11 - 26
  • [2] WNT signalling pathways as therapeutic targets in cancer
    Anastas, Jamie N.
    Moon, Randall T.
    NATURE REVIEWS CANCER, 2013, 13 (01) : 11 - 26
  • [3] Eicosanoid signalling pathways as potential therapeutic targets in gastrointestinal cancer
    Cathcart, Mary-Clare
    Mehigan, Brian
    Mc Cormick, Paul
    Kennedy, Breandan N.
    O'Sullivan, Jacintha
    Pidgeon, Graham P.
    Reynolds, John V.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2012, 30 : S66 - S66
  • [4] JNK signalling in cancer: in need of new, smarter therapeutic targets
    Bubici, Concetta
    Papa, Salvatore
    BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (01) : 24 - 37
  • [5] Therapeutic targets in renal cell cancer
    Lambea-Sorrosal, JJ
    Lara, R
    Lastra, R
    Ortega, E
    Aguirre, E
    Mayordomo, JI
    Godino, J
    Santos, I
    Storkus, W
    Tres, A
    ANNALS OF ONCOLOGY, 2005, 16 : 291 - 291
  • [6] Cancer cell metabolism: implications for therapeutic targets
    Jang, Miran
    Kim, Sung Soo
    Lee, Jinhwa
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2013, 45 : e45 - e45
  • [7] Therapeutic targets in cancer cell metabolism and death
    I Iaccarino
    L M Martins
    Cell Death & Differentiation, 2011, 18 : 565 - 570
  • [8] Cell cycle kinases as therapeutic targets for cancer
    Silvia Lapenna
    Antonio Giordano
    Nature Reviews Drug Discovery, 2009, 8 : 547 - 566
  • [9] Cell death pathways as therapeutic targets for cancer
    Karantza-Wadsworth, V.
    Patel, S.
    Jin, S.
    Rubin, E.
    White, E.
    EJC SUPPLEMENTS, 2006, 4 (12): : 124 - 124
  • [10] Therapeutic targets in cancer cell metabolism and autophagy
    Heesun Cheong
    Chao Lu
    Tullia Lindsten
    Craig B Thompson
    Nature Biotechnology, 2012, 30 : 671 - 678